Topical corticosteroids as adjunctive therapy for bacterial keratitis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Herretes, Samantha ^a   Wang, Xue ^b   Reyes, Johann M G ^c,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of Internal Medicine   (Philippines)

^d UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO;

ADJUVANT THERAPY; BACTERIAL KERATITIS; CANADA; CLINICAL OUTCOME; CORNEA DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; FOLLOW UP; HUMAN; INDIA; INTERMETHOD COMPARISON; INTRAOCULAR HYPERTENSION; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOUTH AFRICA; SYSTEMATIC REVIEW; UNITED STATES; VISUAL ACUITY; ADJUVANT CHEMOTHERAPY; EYE INFECTIONS, BACTERIAL; KERATITIS; META ANALYSIS; MICROBIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; CHEMOTHERAPY, ADJUVANT; EYE INFECTIONS, BACTERIAL; HUMANS; KERATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 84951288114     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005430.pub3     Document Type: Review

References (72)

1. Blair J, Hodge W, Al-Ghamdi S, Balabanian R, Lowcock B, Pan YI, et al. Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. Canada Journal of Ophthalmology 2011;46(1):40-5.
2. Hodge WG, Blair J, Al-Ghambdi S, Balabanian R, Lowcock BC, Pan YI, et al. Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: a double-blinded, randomized clinical trial - interim report. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 4275.
3. Carmichael TR, Gelfand Y, Welsh NH. Topical steroids in the treatment of central and paracentral corneal ulcers. British Journal of Ophthalmology 1990;74(9):528-31.
4. Acharya N, Srinivasan M, Mahalakshmi R, Jayashree D, Prajna L, House J, et al. Steroids for Corneal Ulcers Treatment - SCUT pilot study results. Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 4752.
5. Chen A, Prajna L, Srinivasan M, Acharya N, Lietman T. Does in vitro susceptibility testing predict clinical outcomes in bacterial keratitis? Results from the Steroids for Corneal Ulcers Trial (SCUT) pilot study. Investigative Ophthalmology and Visual Science 2007;48:ARVO E-Abstract 4277.
6. Dulku S. Subgroup analysis in the steroids for corneal ulcers trial. Archives of Ophthalmology 2012; Vol. 130, issue 6:807-8.
7. Garg P, Vazirani J. Can we apply the results of the Steroid Corneal Ulcer Trial to Nocardia infections of the cornea?. Expert Review of Ophthalmology 2013;8(1):41-4.
8. Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clinical Infectious Diseases 2012;54(10):1381-7.
9. Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Priya JL, et al. Nocardia keratitis: clinical course and effect of corticosteroids. American Journal of Ophthalmology 2012;154(6):934-9.
10. McClintic SM, Prajna NV, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, et al. Visual outcomes in treated bacterial keratitis: four years of prospective follow-up. Investigative Ophthalmology and Visual Science 2014;55(5):2935-40.
11. Oldenburg CE, Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, et al. Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis. Investigative Ophthalmology and Visual Science 2013;54(2):1522-6.
12. Ray KJ, Prajna L, Srinivasan M, Geetha M, Karpagam R, Glidden D, et al. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis. JAMA Ophthalmology 2013;131(3):310-3.
13. Ray KJ, Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden DV, et al. Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmology 2014;132(6):737-41.
14. See CW, Srinivasan M, Saravanan S, Oldenburg CE, Esterberg EJ, Ray KJ, et al. Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial. Ophthalmic Epidemiology 2012;19(6):407-13.
15. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, et al. Corticosteroids for bacterial keratitis - The Steroids for Corneal Ulcers Trial (SCUT). Archives of Ophthalmology 2012;130(2):143-150.
16. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, et al. The Steroids for Corneal Ulcers Trial: study design and baseline characteristics. Archives of Ophthalmology 2012;130(2):151-7.
17. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O'Brien KS, et al. The Steroids for Corneal Ulcers Trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. American Journal of Ophthalmology 2014;157(2):327-33.
18. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Ray KJ, et al. Visual recovery in treated bacterial keratitis. Ophthalmology 2014;121(6):1310-1.
19. Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, et al. Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment. Investigative Ophthalmology and Visual Science 2012;53(1):267-72.
20. Srinivasan M, Lalitha P, Mahalakshmi R, Prajna NV, Mascarenhas J, Chidambaram JD, et al. Corticosteroids for bacterial corneal ulcers. British Journal of Ophthalmology 2009;93(2):198-202.
21. Barequet IS, Jabbur NS, Barron Y, Osterhout GJ, O'Brien TP. Perioperative microbiologic profile of the conjunctiva in photorefractive keratectomy. Journal of Refractive Surgery 2001;17(1):55-62.
22. Buhren J, Baumeister M, Kohnen T. Diffuse lamellar keratitis after laser in situ keratomileusis imaged by confocal microscopy. Ophthalmology 2001;108(6):1075-81.
23. Callegan MC, O'Callaghan RJ, Hill JM. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clinical Pharmacokinetics 1994;27(2):129-49.
24. Cosar CB, Sener AB, Sen N, Coskunseven E. The efficacy of hourly prophylactic steroids in diffuse lamellar keratitis epidemic. Ophthalmologica 2004;218(5):318-22.
25. Dighiero PL, Merciã M, Gicquel J. Early use of amniotic membrane transplantation combined with topical steroids in severe bacterial keratitis. Investigative Ophthalmology and Visual Science 2005;45:ARVO E-abstract 2767.
26. Goldberg RA, Li TG. Postoperative infection with group A beta-hemolytic Streptococcus after blepharoplasty. American Journal of Ophthalmology 2002;134(6):908-10.
27. Gris O, Guell JL, Wolley-Dod C, Adan A. Diffuse lamellar keratitis and corneal edema associated with viral keratoconjunctivitis 2 years after laser in situ keratomileusis. Journal of Cataract and Refractive Surgery 2004;30(6):1366-70.
28. Hanada K, Shimazaki J, Shimmura S, Tsubota K. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. American Journal of Ophthalmology 2001;131(3):324-31.
29. Hoffman RS, Fine IH, Packer M. Incidence and outcomes of LASIK with diffuse lamellar keratitis treated with topical and oral corticosteroids. Journal of Cataract and Refractive Surgery 2003;29(3):451-6.
30. Morlet N, Minassian D, Butcher J. Risk factors for treatment outcome of suspected microbial keratitis. Ofloxacin Study Group. British Journal of Ophthalmology 1999;83(9):1027-31.
31. Nakajima H, Yamada M, Mashima Y. Review of infectious keratitis following keratoplasty. Japanese Journal of Clinical Ophthalmology 2001;55(5):1001-6.
32. Shulman DG, Sargent JB, Stewart RH, Mester U. Comparative evaluation of the short-term bactericidal potential of a steroid-antibiotic combination versus steroid in the treatment of chronic bacterial blepharitis and conjunctivitis. European Journal of Ophthalmology 1996;6(4):361-7.
33. Vajpayee RB, Sharma N, Chand M, Tabin GC, Vajpayee M, Anand JR. Corneal superinfection in acute hemorrhagic conjunctivitis. Cornea 1998;17(6):614-7.
34. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis: an evidence-based update. Ophthalmology 2002;109(5):835-42.
35. Zegans ME, Toutain C, Saine P, Srinivasan M, Jayashree D, Mahalakshmi R, et al. Analysis of digital images of corneal ulcers in the pilot study for the Steroid Corneal Ulcer Trial (SCUT). Investigative Ophthalmology and Visual Science 2006;47:ARVO E-abstract 1885.
36. NCT01721694. Association of azithromycin 1, 5% loteprednol 0, 5% eye drops versus individual administration of azithromycin 1, 5% and loteprednol 0, 5% in the treatment of ocular inflammation and infection. clinicaltrials.gov/show/NCT01721694 (accessed 3 December 2013).
37. American Academy of Ophthalmology. American Academy of Ophthalmology Final Program (conference abstracts), Chicago. San Francisco, USA: American Academy of Ophthalmology, 2003.
38. Bacterial keratitis Preferred Practice Pattern (PPP) guideline. American Academy of Ophthalmology 2013.
39. Baker RS, Flowers CW Jr, Casey R, Fong DS, Wilson MR. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Archives of Ophthalmology 1996;114(5):632-3.
40. Bennett HG, Hay J, Kirkness CM, Seal DV, Devonshire P. Antimicrobial management of presumed microbial keratitis: guidelines for the treatment of central and peripheral ulcers. British Journal of Ophthalmology 1998;82(2):137-45.
41. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. British Journal of Ophthalmology 2003;87(7):834-8.
42. Burton MJ, Pithuwa J, Okello E, Afwamba I, Onyango JJ, Oates F, et al. Microbial keratitis in East Africa: why are the outcomes so poor?. Ophthalmic Epidemiology 2011;18(4):158-63.
43. Chirambo MC, Tielsch JM, West KP Jr, Katz J, Tizazu T, Schwab L, et al. Blindness and visual impairment in Southern Malawi. Bulletin of the World Health Organization 1986;64(4):567-72.
44. Dart JK, Stapleton F, Minassian D. Contact lenses and other risk factors in microbial keratitis. Lancet 1991;338(8768):650-3.
45. Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Feng CM. The causes of blindness by corneal diseases in 3499 cases. Chinese Journal of Eye Science [Zhonghua Yan Ke Za Zhi] 1990;26(3):151-3.
47. Gangopadhyay N, Daniell M, Weih L, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. British Journal of Ophthalmology 2000;84(4):378-84.
48. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
49. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 1996;103(11):1854-62.
52. Hyon JY, Joo MJ, Hose S, Sinha D, Dick JD, O'Brien TP. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Archives of Ophthalmology 2004;122(8):1166-9.
53. Kaliamurthy J, Kalavathy CM, Parmar P, Nelson Jesudasan CA, Thomas PA. Spectrum of bacterial keratitis at a tertiary eye care centre in India. BioMed Research International 2013:Article ID 181564.
54. Killingsworth DW, Stern GA, Driebe WT, Knapp A, Dragon DM. Results of therapeutic penetrating keratoplasty. Ophthalmology 1993;100(4):534-41.
55. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. American Journal of Ophthalmology 2003;136(3):500-5.
56. Lee YS, Tan HY, Yeh LK, Lin HC, Ma DH, Chen HC, et al. Pediatric microbial keratitis in Taiwan: clinical and microbiological profiles, 1998-2002 versus 2008-2012. American Journal of Ophthalmology 2014;157(5):1090-6.
57. Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. American Journal of Ophthalmology 2005;139(4):730-3.
58. Moeller CT, Branco BC, Yu MC, Farah ME, Santos MA, Hofling-Lima AL. Evaluation of normal ocular bacterial flora with two different culture media. Canadian Journal of Ophthalmology 2005;40(4):448-53.
59. Musch DC, Sugar A, Meyer RF. Demographic and predisposing factors in corneal ulceration. Archives of Ophthalmology 1983;101(10):1545-8.
60. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Archives of Ophthalmology 1995;113(10):1257-65.
61. The Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology 1997;104(11):1902-9.
62. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. American Journal of Ophthalmology 1993;115(4):471-7.
63. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
64. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. American Journal of Ophthalmology 1992;114(5):630-2.
65. Poggio EC, Glynn RJ, Schein OD, Seddon JM, Shannon MJ, Scardino VA, et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. New England Journal of Medicine 1989;321(12):779-83.
66. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
67. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. British Journal of Ophthalmology 2001;85(7):842-7.
68. Schein OD, Ormerod LD, Barraquer E, Alfonso E, Egan KM, Paton BG, et al. Microbiology of contact lens-related keratitis. Cornea 1989;8(4):281-5.
69. Tuli SS. Topical corticosteroids in the management of bacterial keratitis. Current Ophthalmology Reports 2013;1(4):190-3.
70. Vajpayee RB, Dada T, Saxena R, Vajpayee M, Taylor HR, Venkatesh P, et al. Study of the first contact management profile of cases of infectious keratitis: a hospital-based study. Cornea 2000;19(1):52-6.
71. Suwan-apichon O, Reyes JM, Chuck RS, Herretes S, Vedula SS. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005430]
72. Suwan-Apichon O, Reyes JM, Herretes S, Vedula SS, Chuck RS. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005430.pub2]